FDA Approves First Targeted Treatment For Bile Duct Cancer

The U.S. Food and Drug Administration (FDA) granted accelerated approval to Incyte Corp.'s Pemazyre (pemigatinib) as the first treatment approved for adults with certain types of previously treated, advanced cholangiocarcinoma, a cancer of bile ducts. While approving Pemazyre, the FDA considered the overall risk to benefit assessment for patients with tumors harboring FGFR2 gene fusions.

from RTT - Biotech https://ift.tt/3bAfqEZ
via IFTTT